ArticleProgress in orthodontics2024
Effect of anti-sclerostin antibody on orthodontic tooth movement in ovariectomized rats.
Article in Progress in orthodontics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Role of Wnt Signaling in Age-Related Alveolar Bone Loss and Regeneration.Journal of periodontal research · 2026Review
- Effect of Orthodontic Tooth Movement on Sclerostin Expression in Alveolar Bone Matrix: A Systematic Review of Studies on Animal Models.Dentistry journal · 2025Review
- Proteomic Analysis of the Periodontal Ligament During Orthodontic Movement: A Study in Rats.Proteomes · 2025Article
- Correction to: Effect of anti-sclerostin antibody on orthodontic tooth movement in ovariectomized rats.Progress in orthodontics · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the effect of systemically administered anti-sclerostin antibodies (Anti-Scl Ab) on orthodontic tooth movements (OTM) in an ovariectomized rat.
methodsTwenty-four 12-week-old female Sprague-Dawley rats were randomly divided into two groups: (1) ovariectomy (OVX) group, (2) ovariectomy + romosozumab (ROMO) group. OTM was performed 8 weeks after OVX. The ROMO group received subcutaneous injections of romosozumab twice a week, starting two weeks after OVX. Eight weeks after the OVX, an orthodontic force of 50 g was measured and applied by connecting orthodontic elastic bands between the maxillary first molar and a mini-screw to facilitate tooth movement (orthodontic treatment). Subsequently, the three rats were sacrificed on days 5, 7, 10, and 14. The plaster models were scanned to measure the amount of tooth movement. The effects on alveolar bone and periodontal tissues were evaluated through micro-computed tomography (micro-CT) analysis, tartrate-resistant acid phosphatase (TRAP) staining, and immunohistochemistry (IHC) analysis.
resultsThe ROMO group showed more tooth movement on day 7 of orthodontic treatment. Conversely, on days 10 and 14, relatively less movement was observed. Analysis of the root furcation area of the maxillary first molars revealed that from the 7th day, BV/TV, Tb.N., Tb.Th. increased, while Tb.Sp. decreased in the ROMO group. More TRAP-positive cells were observed in the compression side of the OVX group, the ROMO group exhibited a marked decrease in the positive expression of the RANKL, OPG, and sclerostin. The OPG/RANKL ratio showed significant differences in expression between the two groups. The ROMO group exhibited a higher OPG/RANKL ratio than the OVX group, and the tension side exhibited a higher OPG/RANKL ratio demonstrating significant differences.
conclusionRomosozumab initially accelerated tooth movements, but later decreased tooth movement. As new alveolar bone is formed, the micro-CT parameters are also improved. Osteoclasts, RANKL, OPG, and sclerostin decreased, while the OPG/RANKL ratio became higher.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.